Satellos Bioscience opens the market

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Satellos, a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders, went public on the TSX. Frank Gleeson, Co-Founder and Chief Executive Officer, Satellos Bioscience, and his team joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market.

Satellos is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Gotcare's program evaluation at Women's College Hospital improves healthcare accessibility for homebound older adults
Next

KA Imaging’s Reveal Mobi Pro receives Canadian Medical Device Licence from Health Canada